PARNAXLAB127.95

Parnax Lab Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHKPLMAKERSLNOVARTINDSGRLSHUKRAPHARSUNLOC
View
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
Non-current Assets
+ Property, Plant & Equipment0.40.50.4
+ Other Intangibles0.00.00.0
+ Non-current Investments0.10.10.1
+ Other Non-current Financial Assets0.00.00.0
Current Assets
+ Inventories0.60.90.8
+ Cash & Cash Equivalents1.30.40.5
+ Other Bank Balances0.00.00.8
+ Short-term Loans2.95.37.0
+ Other Current Assets0.60.80.8
Total Assets21.422.224.7
Equity
+ Equity Share Capital11.511.511.5
+ Other Equity / Reserves7.99.711.1
Liabilities
+ Deferred Tax Liabilities0.4
+ Trade Payables0.40.71.3
+ Other Current Financial Liab0.40.30.2
+ Other Current Liabilities0.10.10.2
Total Equity & Liabilities21.422.224.7
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY25 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.